経口固形水素カプセルによる慢性炎症への影響：パイロット観察研究
This pilot observational study enrolled 30 outpatients with chronic inflammatory conditions, randomized into low-, medium-, and high-dose groups (n=10 each) receiving oral solid hydrogen capsules (OSHCs) for four weeks. In vitro characterization showed that OSHCs maintained a sustained reduction in oxidative reduction potential for 60 minutes and released hydrogen gradually over 24 hours, outperforming hydrogen-rich water and calcium hydride-treated water. The primary endpoint, erythrocyte sedimentation rate at 120 minutes (ESR120), declined significantly in the high-dose group (p=0.016), while C-reactive protein showed a decreasing trend across all groups after four weeks (p=0.077). Secondary endpoints including the Disease Activity Score 28 (DAS28), the Brief Fatigue Inventory-Taiwan (BFI-T), and the diabetes control scale (CSSD70) all improved following supplementation. These findings suggest that OSHC supplementation may confer anti-inflammatory and antioxidant benefits in individuals with chronic low-grade inflammation.
OSHCs are proposed to release molecular hydrogen gradually in the gastrointestinal tract, selectively scavenging reactive oxygen species and lowering oxidative reduction potential, thereby suppressing systemic inflammatory markers such as ESR and CRP.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/39310256